Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 73.22% | 168.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.76% | 57.10% | |||
| Operating Income | -30.76% | -57.10% | |||
| Income Before Tax | -18.94% | -61.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.94% | -61.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.94% | -61.50% | |||
| EBIT | -30.76% | -57.10% | |||
| EBITDA | -30.91% | -58.46% | |||
| EPS Basic | -18.95% | -61.48% | |||
| Normalized Basic EPS | -23.06% | -57.17% | |||
| EPS Diluted | -18.95% | -61.48% | |||
| Normalized Diluted EPS | -23.06% | -57.17% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||